EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
about
EZH2 methyltransferase and H3K27 methylation in breast cancerAn overview of long non-coding RNAs in ovarian cancersStructural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET DomainPrognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisDiverse involvement of EZH2 in cancer epigeneticsMining TCGA data using Boolean implicationsPolycomb group expression signatures in the malignant progression of gliomas.MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinomaEZH2: not EZHY (easy) to deal.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancerEZH2 depletion blocks the proliferation of colon cancer cells.TGF-β mediated DNA methylation in prostate cancer.Regulation and Role of EZH2 in CancerThe role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell linesOvarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.EZH2, a unique marker of malignancy in effusion cytology.EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 geneEnhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysisEnhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma.The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression.TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene ExpressionRole of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic TargetEZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro.RanBP9/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcomaDLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.Histone onco-modifications.Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma.Update of research on the role of EZH2 in cancer progression.Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer.Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
P2860
Q24633788-CEC0AE7D-2166-4344-840A-F08F2C341BA0Q26753467-DC6C5748-765B-439A-8914-C09629AEC91DQ27681087-B2333B2C-FB87-4ACC-B76C-4BD9CB3AA416Q27853296-5D959AC5-CE54-4002-99FA-7E4881A6DF12Q28084911-CF310A00-412A-4E03-9126-5CF1C44678B3Q30838107-969231F6-87CE-4A93-8AAD-6241BF98E387Q33599449-E67346CF-AE89-4F9D-BCA4-1854ADD809C0Q33609359-4BB97D65-7C1A-46BB-8B83-E8871A311B91Q33610902-02192CCD-8CFF-43F8-BFB4-BA317D21151FQ33741828-148A5861-81FB-48CF-A717-8191811D1E66Q33804215-34D5B326-D62D-4427-A613-EE39C409269CQ33875597-9A7D5796-2BA3-49B2-903F-F92CBD96A8D7Q33963796-47798DA7-0045-4E0B-9E11-5834186686F9Q34039935-9F37F1A3-6593-4FC5-AE67-648811A45097Q34043370-0F957583-B0FE-4BB2-ACD5-E8587F98C4FAQ34137728-A44996EF-CCD9-4BE4-B0A3-3542EEC7F5B2Q34201826-3CBEF390-8E4C-4ACA-B2CE-36D0F3BE17D5Q34569371-F8D018F2-D2A1-4EDB-8A31-3AEAD45C41F4Q34699488-FE7D4BF6-E149-490B-B3CA-72EBF5E7CEBDQ34789991-6FB187F0-9E86-4AB2-B5AE-6E4607EB38E9Q35606640-F3DEC229-6BB0-4444-822D-E9137174DCD8Q35942323-35E9444A-3145-4847-8213-19814AB0C98DQ35955196-BC51F56A-3132-4C46-8894-9539A84D6F5DQ36105152-3CAE7085-ED13-48AB-A132-C8CE2092AD2CQ36338683-EC0C797E-348B-4E88-A49B-A1709A3C188AQ36439839-1CD12DAF-91F4-42BB-BC44-8D0D93CB2052Q36679745-BFDA5667-BCE9-4B88-A089-C583061935B5Q36998193-9F110639-0798-46FD-8F70-B136CD5E13D4Q37071469-A6440AAB-4BA7-45C7-A2A9-A081A6303D8AQ37603522-24D09A34-9AA9-41FF-A3E2-C22EA8ECC921Q37697488-C25E7CCC-CDF1-4F4F-ABA6-19DA57C5FC33Q37708968-545F1409-BA81-46DA-95D2-66F8BCFBBC95Q37868421-FBF9C3E1-E0F6-4B68-8F38-37731B6C344AQ38085112-5EBC5DE1-8B00-4770-9BFD-9F2BEAF38992Q38099319-94CF0216-7AC3-460B-9478-8A456BA34F43Q38232172-4E41A2F4-AAE3-48E0-AD59-3F6E43199037Q38287628-A2E0B49F-06B0-47DE-A1FE-CA22D1BC33FEQ38326633-81443FBC-9D63-4A2D-85BD-0DF489205583Q38674708-38909F8A-83B5-43B3-B42F-C5BD19BC7F6DQ38733932-55FC1E7B-8B13-4F29-9163-4448F2969486
P2860
EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@en
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@nl
type
label
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@en
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@nl
prefLabel
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@en
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients.
@nl
P2093
P2860
P356
P1433
P1476
EZH2 supports ovarian carcinom ...... in ovarian carcinoma patients
@en
P2093
Guo-Fen Yang
Hai-Xia Deng
Hsiang-Fu Kung
Mu-Yan Cai
Shi-Juan Mai
Wen-Feng Hua
Yang-Chao Chen
Yi-Ji Liao
P2860
P304
P356
10.1093/CARCIN/BGQ150
P407
P577
2010-07-28T00:00:00Z